Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as an injectable solution for intravenous use. It treats various solid tumors such as bladder, gastric, pancreatic and breast cancers in adult patients.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is an antineoplastic antibiotic used in the treatment of solid tumors.

- Bladder cancer: employed as part of combination therapy to reduce tumor recurrence after surgery. - Gastric cancer: used in advanced disease to inhibit tumor growth. - Pancreatic cancer: administered intravenously to improve response when combined with other chemotherapeutics. - Breast cancer: incorporated into regimens for metastatic or refractory disease.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis requiring anti‑emetic support. - Myelosuppression: decreased white blood cells, platelets, and red cells. - Alopecia: temporary hair loss during treatment. - Fatigue: generalized tiredness affecting daily activities. - Renal toxicity: transient elevation of serum creatinine.

Serious or Rare Side Effects: - Severe bone‑marrow suppression: prolonged pancytopenia requiring transfusion. - Pulmonary fibrosis: progressive lung scarring with dyspnea. - Hemolytic‑uremic syndrome: hemolysis, renal failure, and thrombocytopenia. - Anaphylactic reactions: sudden hypotension, rash, or airway compromise. - Secondary malignancies: rare development of therapy‑related cancers. - Severe mucositis: painful oral and gastrointestinal ulceration.

Prior to initiating Mitomycin therapy, several safety considerations should be reviewed.

- Renal function: assess baseline creatinine and adjust dose if impairment is present. - Hematologic status: obtain complete blood count to monitor for myelosuppression. - Pulmonary health: evaluate lung function in patients with pre‑existing respiratory disease. - Concurrent radiation: avoid overlapping high‑dose radiation fields to reduce tissue toxicity. - Pregnancy and lactation: contraindicated unless benefits clearly outweigh potential fetal or neonatal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Mitomycin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Other DNA‑cross‑linking agents (e.g., cyclophosphamide): may amplify bone‑marrow toxicity. - High‑dose radiation therapy: increases risk of severe tissue damage. - Strong CYP2C9 inhibitors: may alter metabolic clearance in rare cases.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to thrombocytopenia. - Nephrotoxic drugs (e.g., aminoglycosides): additive renal impairment. - Immunosuppressants (e.g., cyclosporine): heightened infection susceptibility.